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Introduction: As prospective data on long-term patient-reported outcome measures
(PROMs) to assess Health related Quality of Life (HRQoL) after stroke are still scarce, this
study examined the long-term course of PROMs and investigated influential factors such
as recanalization therapies.
Materials and Methods: A total of 945 (mean age 69 years; 56% male) stroke patients
were enrolled with a personal interview and chart review performed at index event. One
hundred forty (15%) patients received thrombolysis (IVT) and 53 (5%) patients received
endovascular therapy (ET) or both treatments as bridging therapy (BT). After 3 and 12
months, a follow-up was conducted using a postal questionnaire including subjective
quality of life EQ-5D-5L (European Quality of Life 5 Dimensions). At all time-points,
Modified Rankin Scale (mRS) was additionally used to quantify functional stroke severity.
Differences between therapy groups were identified using post-hoc-tests. Linear and
logistic regression analyses were used to identify predictors of outcomes.
Results: Recanalization therapies were associated with significant improvements
of NIHSS (National Institutes of Health Stroke Scale [regression coefficient IVT 1.21
(p = 0.01) and ET/BT 7.6; p = 0.001] and mRS (modified Rankin Scale) [regression
coefficient IVT 0.83; p = 0.001 and ET/BT 2.0; p = 0.001] between admission and
discharge compared to patients with stroke unit therapy only, with a trend toward
improvement of EQ-5D after 12 months [regression coefficient 4.67 (p = 0.17)] with IVT.
HRQoL was considerably impaired by stroke and increased steadily in 3- and 12-months
follow-up in patients with (mean EQ-5D from 56 to 68) and without recanalization therapy
(mean EQ-5D from 62 to 68). In severe strokes a major and significant improvement was
only detected during period of 3 to 12 months (p = 0.03 in patients with and p = 0.005
in patients without recanalization therapy).
Conclusions: Despite significant and continuous improvements after stroke the HRQoL
after 12 months remained below the age-matched general population, but was still
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unexpectedly high in view of the accumulation of permanent disabilities in up to 30% of
the patients. Especially in severe strokes, it is important to evaluate HRQoL beyond a
3-months follow-up as improvements became significant only between 3 months and
1 year.
Keywords: stroke, disability, patient-reported outcome measures (PROMs), endovascular therapy (EVT),
thrombolyic therapy
INTRODUCTION
Approximately 15 million people suffer a stroke every year. A
high proportion of the cases is fatal, and one-third of stroke
patients is affected by a serious, permanent disability (1). In
Germany, stroke is the third-leading cause of death, with more
than 60,000 fatalities out of ∼260,000 cases (first-ever and
recurrent strokes) each year (2). Nearly three-quarters of all
strokes occur in people over the age of 65, with a decreasing
chance of complete recovery or good functional outcome with
increasing age (3). These numbers illustrate the importance of
factors influencing patient outcomes, especially in the long run.
In the vast majority of stroke-related outcome studies,
so-called clinician-reported outcome parameters like the
modified Rankin Scale (mRS) quantify the patients’ functional
status. Although commonly used, this scale does not cover
the patient’s cognitive and social functions (4), nor essential
domains such as symptom burden (e.g., fatigue) or emotional
health (e.g., depression). Therefore, the mRS only provides
limited information about the health status from the
patient’s perspective.
Patient-reported outcome measures (PROMs) specifically
address the patient’s view without interpretation by clinicians
or anyone else (5). Health-related quality of life (HRQoL)
can be assessed either with generic questionnaires, which
can be applied to persons irrespective of a certain disorder,
or with disease-specific measures, which are developed to
capture the specific impairments associated with certain disease.
Generic questionnaires allow comparisons across patients with
different diseases and the general population. Moreover, generic
questionnaires which are very short and easy to complete are
available. This is an essential requirement when assessingHRQoL
in the hospital setting after a severe acute event such as a
stroke. The EuroQol Group 5-Dimension (EQ-5D) is a generic
questionnaire which has already been applied and validated in
patients with stroke (6–10). In this study we used EQ-5D-5L,
which was introduced in 2005 as a new version of EQ-5D with
increased reliability and sensitivity compared to EQ-5D-3L (11).
It consists of two parts: the EQ-5D-5L descriptive system and a
visual analog scale (EQ VAS). The descriptive system contains
five questions about the severity in each of the five EQ-5D
domains mobility, self-care, usual activities, pain/discomfort and
anxiety/depression which can be combined into a single utility
Abbreviations: NIHSS, National Institutes of Health Stroke Scale; mRS, modified
Ranking Scale; PROMs, patient-reported outcome measures; HRQoL, health-
related quality of life; EQ VAS, European Quality of Life 5 Dimensions visual
analogue scale; IVT, intravenous thrombolysis; ET, endovascular therapy; BT,
bridging therapy.
value (EQ-5D index). The EQVAS provides an overall assessment
of the current general health state. Completing the questionnaire
does not take longer than 3–5min in average. Information on
PROMs allow clinicians to improve shared decision-making
and provide individualized care to improve the patient’s health-
related quality of life (HRQoL) (4).
Intravenous thrombolysis therapy (IVT) and the recent
implementation of endovascular thrombectomy (ET) as well
as their combination termed “bridging therapy” (BT) led to a
significant improvement in the short-term functional outcome of
these severely affected subgroups of ischemic strokes with large
vessel occlusions of the anterior circulation (12–14).
Yet, prospective data regarding the long-term impact on
PROMs are almost entirely lacking in this patient population.
Therefore, we focused on the analysis of PROMs and
disabilities in the long-term outcome of stroke patients in




Every year, ∼1,700 patients with acute strokes are treated at the
University Hospital Augsburg. It was estimated that about 60–
70% of the patients would take part in the study (15). Thus, we
assumed that about 900–1,000 patients could be recruited within
the study period of 1 year. With an estimated effect estimate
(HR) of 1.7 for the covariate of interest, a variance of 0.36 and
a rho² = 0.3, the inclusion of 997 patients would be sufficient to
detect a significant difference with a statistical power of 80% at a
significance level of 5%.
Study Population, Data Collection and
Follow-Up
Between September 2018 and November 2019, all consecutive
adult patients (18 years and older) with an incident as well as
recurrent ischemic or hemorrhagic stroke, who were admitted
to the University Hospital of Augsburg, were screened for
enrollment. Proportions of baseline and follow-up assessment
are shown in Figure 1. Detailed information about methods for
recruitment, conduction of patient interviews and obtainment of
follow-up data has been published elsewhere (15).
In summary, trained study nurses prospectively recorded
all stroke cases and interviewed patients or legal caregivers
after written informed consent. In the interview, demographic
information, symptoms upon presentation, diagnosis, lifestyle
factors and comorbidities (e.g., carcinoma, cardiac comorbidity,
diabetes mellitus) were gathered. Clinical data on comorbidities,
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FIGURE 1 | Consort chart of patient enrollment and follow-up.
risk factors, medication prescribed before hospital stay and
at discharge, diagnostic procedures, clinical characteristics,
disabilities, laboratory parameters, and treatment regimens
during the hospital stay were additionally registered by a
chart review.
Three and 12 months after hospital discharge, all study
participants received postal questionnaires or telephone
interviews with questions on disease symptoms, disabilities,
physical activity (German-PAQ-50+) (16), health-related quality
of life measured with EQ-5D-5L (European Quality of Life 5
Dimensions) (7, 17) recurrent events and healthcare utilization.
Outcomes
During inpatient stay, clinical outcomes were measured using the
National Institute of Health Stroke Scale (NIHSS: score range
0–42) and mRS [score range 0 (no functional deficits) to 6
(deceased)] with higher scores indicating a greater neurological
deficit or a higher degree of physical disability (18, 19). NIHSS
and mRS were recorded from the patient chart at the timepoints
of hospital admission and discharge.
Patient-reported health status was assessed by a visual analog
scale (EQ VAS), which evaluates the patient’s current overall
subjective health from 0 (worst imaginable health) to 100 (best
possible health). EQ-5Dwas assessed in the subacute stroke phase
at the end of inpatient stay.
Reliability and validity of the main measures NIHSS (18, 20),
mRS (19, 20) and EQ-5D (6–10) used in this study are confirmed
in the literature, both in its original and German version: In
detail, interrater reliability of NIHSS [mean κ (kappa) = 0.80
in German version (20) and κ = 0.95 in original version (18)]
and mRS [mean κ = 0.76 in German version (20) and κ = 0.78
in original version (19)] is very high, as well as the intraclass
correlations of EQ-5D ranging from 0.67 to 0.8 (8).
Additionally, information on care dependency (e.g., eligibility
of a disabled person’s card) and use of medical aids (e.g., walking
stick or wheelchair) was collected.
In the follow-up stage, mRS as a functional outcome and
EQ-5D assessing the patients’ subjective health status, were both
evaluated by a postal questionnaire sent to the patients after 3 and
12 months.
Statistical Analysis
Baseline characteristics are presented as mean ± standard
deviation (SD) for normally distributed or median ±
interquartile range (IQR) for non-normally distributed
continuous variables and percentage for categorical variables
(Table 1). In a first step, Chi²-Tests were performed for
categorical variables if each cell contained at least 5 expected
values. If this was not the case, a Fisher’s exact test was calculated.
Continuous variables were tested for normal distribution
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TABLE 1 | Baseline characteristics of stroke patients with and without
recanalization therapy [thrombolysis (IVT), endovascular therapy (ET) or bridging
therapy (BT)].








Number of patients (945) 193 (20) 752 (80)
Interviews and file processing
(787)–no. (%)
158 (82) 629 (84)
File processing only (158)–no.
(%)
35 (18) 123 (16)
Characteristics
Age (945)–mean (SD) by
years
71 (12) 69 (13) 0.09d
• > 80 years - no. (%) 50 (26) 184 (25)
• 50–79 years - no. (%) 136 (70) 508 (67)
• <50 years - no. (%) 7 (4) 60 (8)
Sex (945)–no. (%) 0.06a
• Female 96 (50) 318 (42)
• Male 97 (50) 434 (58)




88 (46) 381 (51) 0.48a
Hypertension
(945)–no. (%)
163 (85) 601 (80) 0.15a
Atrial fibrillation
(945)–no. (%)
47 (24) 141 (19) 0.08a
Hyperlipidemia
(920)–no. (%)
91 (48) 356 (49) 0.83a
Diabetes mellitus
(936)–no. (%)





• Ischemic 193 (100) 715 (95)




• Macroangiopathic 47 (25) 176 (26)
• Microangiopathic 31 (16) 132 (19)
• Cardio-embolic 66 (35)** 153 (22)**
• Others 3 (1) 18 (3)




4 (7) 1 (3) 0.001c
NIHSS discharge (834)–median
(IQR)
1 (2) 0 (1) 0.001c
mRS admission (895)–no. (%) 0.001b
• 0 1 (1)** 139 (20)**
• 1 10 (5)** 144 (21)**
• 2 17 (9)** 180 (26)**
• 3 52 (27)** 128 (18)**
• 4 78 (40)** 94 (13)**
• 5 35 (18)** 17 (2)**
(Continued)
TABLE 1 | Continued











• 0 305 (43)** 41 (21)**
• 1 164 (23) 48 (25)
• 2 117 (17) 33 (17)
• 3 64 (9)** 38 (20)**
• 4 45 (6) 20 (10)
• 5 3 (1)** 9 (5)**
• 6 4 (1) 3 (2)
EQ VAS during hospitalization
(752)–mean (SD)
56 (25) 62 (21) 0.03d
aChi2-test; bFisher’s exact test; cMann-Whitney-U-Test; d t-test for independent samples.
*p-value indicates differences in baseline variables between recanalization therapy (IVT,
ET, BT) and stroke unit therapy only.
**indicates significant differences between recanalization therapy and stroke unit therapy
only of categorical variables.
Significant p-values were highlighted in bold.
using Shapiro-Wilk-Test and Q-Q plots. Non-parametric
Mann-Whitney-U-Tests for non-normally distributed variables
and t-tests for independent samples for normally distributed
variables were used to compare patients with and without
stroke-specific acute therapy. In a second step, differences
between the four treatment groups (IVT, IAT, BT, and no
treatment) were examined using Chi2 or Fisher’s exact test for
categorical variables and non-parametric Kruskal-Wallis-Tests
for continuous variables. If these were significant, treatment
groups were compared pairwise using Bonferroni adjusted
post-hoc-tests.
Patients with hemorrhagic stroke (n = 37; 5%) were excluded
from statistical analyses on stroke severity and follow-up as well
as in regression analyses.
For the identification of the outcome both from clinical
and patient’s perspective, linear regression models were fitted
for improvement of NIHSS and mRS between admission and
discharge as well as EQ VAS during hospitalization, after 3
and 12 months. Ordinal logistic regressions were fitted for
subjective functional limitations after 3 and 12 months. Potential
confounders were defined as variables found in the literature
to be related to the outcome and associated with the exposure
but not intermediate variables in the causal pathway between
exposure and outcome. All regression models were adjusted
for age, sex, highest school-leaving qualification, smoking,
alcohol abuse (with AUDIT-C), physical activity [with IPAQ
(International physical activity questionnaire)] and the presence
of at least one comorbidity. The treatment groups IVT and
IAT/BT were compared to patients without acute therapy. All
model assumptions were fulfilled.
A subgroup analysis including severely affected patients (mRS
3-5) was performed using non-parametric Wilcoxon-Tests to
identify relevant changes in patient-reported health between
follow-up timepoints.
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TABLE 2 | Association between stroke-specific acute therapies and patient
outcome.
Outcome* Effect estimate Adjusted
estimate (95% CI)
p-value
NIHSS improvement between admission and discharge
• IVT Regression
coefficient β
1.21 (0.22 to 2.20) 0.01a
• ET or BT Regression
coefficient β
7.6 (6.14 to 9.11) 0.001a
mRS improvement between admission and discharge
• IVT Regression
coefficient β
0.83 (0.42 to 1.23) 0.001a
• ET or BT Regression
coefficient β
2.0 (1.37 to 2.58) 0.001a






















Subjective functional limitations after 3 months
• IVT Odds ratio 1.43 (0.89 to 2.29) 0.13b
• ET or BT Odds ratio 1.69 (0.84 to 3.44) 0.14b











Subjective functional limitations after 12 months
• IVT Odds ratio 1.00 (0.56 to 1.76) 0.98b
• ET
or combined
Odds ratio 1.75 (0.74 to 4.16) 0.20b
a linear regression; bordinal logistic regression.
*Patients with IVT and ET/BT therapy were compared to patients without
recanalization therapy.
Significant p-values were highlighted in bold.
RESULTS
Study Population at Baseline
During the study period, 945 consecutive patients were included.
Baseline characteristics are shown in Table 1. Patients were
divided into two groups: patients without recanalization therapy
(80%) and patients having received a stroke-specific acute
therapy (15% IVT and 5% ET or BT).
In most of the baseline characteristics, there were no
significant differences between both patient groups. Still, the
following significant difference in stroke etiology and severity was
mentionable: In patients with recanalization therapy, cardiogenic
causes were significantly more frequent compared to patients
with stroke unit therapy only. Patients with stroke-specific acute
therapy had significantly higher NIHSS and mRS values at
admission and discharge and significantly lower EQ VAS values.
TABLE 3 | Follow-up after 3 and 12 months of stroke patients with and without
recanalization therapy [thrombolysis (IVT), endovascular therapy (ET) or bridging
therapy (BT)].




3-month-follow-up (587) – no. (%) 113 (59) 474 (63)
12-month-follow-up (534) – no. (%) 110 (57) 424 (56)
Subjective health status
EQ VAS during hospitalization (752) –
mean (SD)
56 (25) 62 (21)
EQ VAS at 3 months (550) – mean (SD) 65 (22) 67 (19)
EQ VAS change baseline – 3 months
(527) – mean (SD)
8 (20) 4 (21)
EQ VAS at 12 months (500) – mean
(SD)
68 (19) 68 (19)
EQ VAS change baseline – 12 months
(485) – mean (SD)
5 (21) 5 (22)
Objective functional limitations
Disability card at 3 months (554) –
no (%)
24 (21) 113 (26)
Need of care at 3 months (546) –
no (%)
21 (19) 66 (15)
Medical aids (eg. wheelchair) at 3
months (496) – no (%)
36 (33) 99 (26)
Disability card at 12 months (494) –
no (%)
30 (29) 114 (29)
Need of care at 12 months (496) –
no (%)
21 (19) 58 (15)
Medical aids (e.g., wheelchair) at 12
months (441) – no (%)
25 (25) 89 (26)
Association Between Acute Recanalization
Therapies and Outcomes of Stroke
Patients
During Inpatient Stay
The influence of stroke-specific acute therapies on clinical
and patient-reported outcome measures is shown in Table 2.
Recanalization therapies were associated with a significantly
larger clinical improvement in terms of NIHSS and mRS
between admission and discharge compared to patients without
recanalization therapy. At the time point of discharge, the
treatment group had the identical mean NIHSS compared to the
no-recanalization group at admission. Nevertheless, looking at
overall health status from the patient’s perspective, patients with
stroke-specific acute therapy reported significantly lower EQVAS
scores than the group of patients without recanalization therapy
during hospitalization (p= 0.03, see Table 1). After adjusting for
confounding variables, this effect was no longer significant.
Follow Up at 3 and 12 Months
A total of 587 (62%) patients took part in the 3-month follow-
up and 534 (57%) in the 12-months-follow-up. The response rate
of the two groups with and without stroke-specific acute therapy
was similar. The results of the follow-up assessments are shown
in Table 3.
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FIGURE 2 | Change of long-term patient-reported overall health (EQ VAS) of stroke patients with and without acute therapy.
TABLE 4 | Long-term course of patient-reported health (EQ VAS) of severely affected patients (mRS 3-5).
Baseline 3-month-FU p-value* 12-month-FU p-value+
EQ VAS – mean (SD) Acute therapy (n = 67) 47 (25) 54 (26) 0.44 68 (20) 0.03
No acute therapy (n = 112) 47 (21) 52 (21) 0.14 72 (15) 0.005
*p-value of EQ VAS between baseline and 3 month follow-up.
+p-value of EQ VAS between 3 and 12 month follow-up.
Significant p-values were highlighted in bold.
Looking at EQ VAS change between baseline and 3 months
follow-up, the patient’s health status increased in both groups,
with no significant changes between therapy or stroke unit
therapy only. After 12 months, EQ VAS of treated patients was
equal to the well-being of patients without recanalization therapy
(mean EQ VAS 68 ± 19 in both groups). Altogether, 56% of
patients with and 48% of patients without recanalization therapy
reported increased overall health between the index event and 12
months on EQ VAS, as visualized in Figure 2.
Subgroup Analysis of Patients With
High-Grade Functional Deficits
Because of the relatively low average mRS in the entire cohort,
we added a subgroup analysis of patients with relevant functional
deficits (mRS 3-5, dependency on assistance in everyday life).
The results are presented in Table 4; Figure 3. EQ VAS
steadily increased during the follow-up period, with a significant
improvement between 3 and 12 months.
Other Parameters With Effect on
Patient-Related Outcomes
Independent from the effect of therapy, patients with higher
age (β = −0.17; 95% CI: −0.32, −0.02; p = 0.02), NIHSS
on admission (β = −0.86; 95% CI: −1.45, −0.27; p = 0.004)
and mRS at discharge (β = −1.82; 95% CI −3.3, −0.34; p
= 0.02) reported significantly lower EQ VAS scores after 3
months. After 12 months a history of at least one previous stroke
(β = −6.30; 95% CI: −11.52, −1.08; p = 0.02) was associated
with significantly worse patient’s health. Stroke etiology had no
significant effect on the patient’s health well-being.
Objective Functional Limitations
Three months after stroke, a high percentage of patients (20–
30%) were permanently dependent on care, had a severely
disabled pass or were dependent on medical aids such as walking
sticks or wheelchairs. After 12 months of recovery from stroke,
the numbers remained high, as shown in Table 3. Since, at
baseline, only six patients (0.8%) lived in assisted living and not
a single patient lived in a nursing home, these limitations were
most likely caused by stroke.
DISCUSSION
This is one of the first prospective cohort studies that has
analyzed long-term outcomes in stroke patients with focus on
HRQoL and effects of acute recanalization stroke therapies.
We could show, that HRQoL continuously improved in all
patient groups. However, the most pronounced effect occurred
between 3 and 12 months after stroke, especially in patients with
relevant functional deficits (mRS 3-5). This observation was valid
independent from stroke-specific acute therapies.
Acute recanalization therapies have a positive effect on
functional deficits after stroke (21, 22). In the present study,
these highly effective therapies strongly impacted short-term
functional deficits, with a significant improvement of NIHSS and
mRS values in patients with recanalization therapy. In average,
this resulted in identical NIHSS values comparing treated
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FIGURE 3 | Long-term course of patient-reported health (EQ VAS) of severely affected patients (mRS 3-5)-representation as boxplots. *Significant differences
between groups.
patients at the timepoint of discharge and only mildly affected
patients with no need of therapy at the time of admission (NIHSS
= 1). With respect to HRQoL, patients in the therapy group had
a significantly lower EQ VAS compared to the stroke patients
without acute therapy, but after adjustment for confounding
variables, patients having profited from recanalization therapies
did not have a significantly different EQ VAS compared to the
patients with stroke unit therapy only, neither in the subacute
phase nor in the follow-up period. At first glance, this was
rather surprising, as another study could detect a prominent
treatment effect, especially for endovascular therapy (23). As
functional deficits and HRQoL correlate in stroke patients (24),
the strong functional improvement during hospitalization in
our treated patients might explain the low treatment effect
in the statistical analysis of the present cohort. The EQ-5D
questionnaire was assessed at the end of inpatient stay when
functional deficits of treated patients were already ameliorated
to a level comparable to the only mildly affected patients in
the no recanalization therapy group. Another aspect might be
that specific treatments might only be one amongst many other
factors influencing patient-centered outcomes. Observational
studies in patients with malignant diseases, e.g., bladder or
breast cancer, revealed a similar effect: age, comorbidities or
psychological distress had a greater influence on EQ-5D than
the specific treatments received (25, 26). For HRQoL individual
coping strategies have a significant impact on the patient’s
subjective well-being. Active coping strategies have a beneficial
effect on HRQoL after stroke with positive aspects being social
support, extrovertive personality traits and active information
seeking (27).
For interpretation of EQ-5D values in stroke patients, it
is necessary to compare these patients to healthy persons
at the same age and to patients with comparable diseases.
Patients in the present cohort rated their overall health status
worse than a representative sample of the age-matched German
population [mean EQ VAS = 75 in persons 60–79 years of
age (28)]. Interestingly, even mildly affected patients without
recanalization treatment (mean NIHSS 2) rated their subjective
health (EQ 62 ± 21) as low as patients with serious diseases
such as advanced colorectal cancer [mean EQ VAS 62 (29)]
or heart disease [mean EQ VAS 61 (28)]. Over time, HRQoL
continued to improve in all patient groups, with the most
significant effect between 3 and 12 months, especially in the
subgroup of patients with severe functional deficits (mRS 3-
5). The EQ VAS level improved to a value of 68 after 12
months, but did not reach the general population’s comparative
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value [mean EQ VAS = 75 (28)]. Our results are in line with
other studies, which found that even after 5 years HRQoL
of stroke survivors remained below the general population
level (30).
Altogether, the present results suggest that a relatively short
follow-up time of 3 months - as recommended in a recent
meta-analysis (22) and practiced in the majority of controlled
trials - may not be sufficient to predict the patients’ long-term
HRQoL. Our data show that this applies for the initially more
severely affected patients of the therapy groups and overall
especially for the subgroup with severe clinical deficits (mRS 3-
5) that needed up to 12 months to recover and improve their
HRQoL. For future evaluation an extended follow-up period
of 24 months is already planned, as we need to increase our
understanding of long-term functional and mental recovery in
stroke patients. HRQoL may continue to improve in the 2nd
year, which is also seen in a study of young stroke patients
(31). As the current literature suggest a poor long-term HRQoL
of stroke survivors (32–34), this information may be of great
value especially for patients with relevant functional deficits.
One explanation for delayed functional recovery, especially
in more severely affected patients, might be the process of
neuronal remodeling, which is restricted in patients with
extended neuronal damage and can be predicted by particular
imaging methods (35). Going along with the observation of
delayed recovery was that the need for medical aids (e.g.,
wheelchair) improved from 33% at 3 months to 25% at 12
months in the therapy group while it remained at 26% for
both time points in the group without recanalization therapy.
Increased mobility might thus be an important factor, whereas
the need of care remained unchanged for both time points at
19 and 15% in the recanalization vs. non-recanalization therapy
group, respectively.
Individual prognosis is essential for patients in the subacute
period after stroke. In our data, younger age and better clinical
outcome measures (NIHSS and mRS) positively influenced EQ
VAS after 3 months. The chance for a good EQ VAS after
12 months was lower in patients with recurrent strokes. In
the current literature, factors such as male sex, white race,
social support and active coping strategies have also been
identified as positive predictors for better HRQoL, whereas stroke
severity and functional impairment were associated with a more
unsatisfactory outcome in stroke survivors (36, 37).
As PROMs reflect the patient-immanent strategies to cope
with a disease, they do not necessarily correlate with objective
outcome parameters such as need for professional care or
medical aids. Interestingly, we observed a discrepancy between
a high level of subjective health quality despite a significant
proportion of our patients being in permanent need of
care 12 months after the index event. These limitations
based on objective criteria should be scrutinized in future
observational outcome studies, as this information is especially
relevant from a health care point of view a high economic
burden for the health care system (38, 39). Standardized
registration of PROMs in the acute and follow-up phase
could improve self-management in patients and support
physicians to gain information about long-term HRQoL in their
patients. To support this, digital measurement systems have
already been tested but further research in this area is still
needed (40).
As a result of our study and the current literature, PROMs
are a valuable supplement, but no substitute to clinician-
reported outcome measures. Despite a considerable proportion
of objective impairments, the subjective health perception
of stroke patients after 1 year is surprisingly high (mean
EQ VAS 68 ± 19) and well above that of other chronic
diseases such as cancer [mean EQ VAS 62 (29)] or heart
disease [mean EQ VAS 61 (28)]. This information is highly
relevant for clinicians when counseling stroke patients and
their relatives.
To guide individualized care concerning PROMs, clinicians
need to know, which patients are at particular risk of long-
term impairment of individual HRQoL. So far, we know that
certain comorbidities as depression (41) and other factors
as unemployment and lack of family support (42) negatively
affect these outcomes. Therefore, physicians should focus
on early interventions of e.g. post stroke depression in the
(sub)acute phase. During rehabilitation and afterwards measures
as reintegration in the job market or implementation of
stroke support groups have a positive effect, as documented
in the literature (43). Other aspects as the level of education
and migrational background still need to be investigated in
future studies.
Strengths and Limitations
The long follow-up period of prospectively analyzed stroke
patients with focus on PROMs combined with the detailed
information on acute stroke treatment and objective functional
limitations represents a major strength of our study.
The use of the EQ-5D enables a comparison with other
diseases. However, the EQ-5D does not allow a detailed
description of specific domains of HRQoL such as social,
cognitive and emotional impairments. Thus, the results
of this study should be confirmed using a more stroke-
specific questionnaire. However, 47% of the consecutive stroke
patients could not be included in the study e.g., due to refusal
(5%) or inability (16%) to participate and 38% of the baseline
assed patients were lost to follow-up. This may produce bias
because more severely affected stroke patients may have been
more likely to refuse participation. The patients in the different
treatment groups are not matched and cannot be compared
directly. This aspect was addressed by a subgroup analysis
of severely affected patients (mRS 3-5) and by adjustment of
confounders in regression models.
Nevertheless, 57% of the patients assessed at baseline
(n = 534) still participated after 12 months. Despite comparable
recanalization therapy rates between our cohort and the Bavarian
average (44), the number of patients with compared to patients
without recanalization therapy was relatively small making it
difficult for smaller effects to become significant.
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CONCLUSION
In conclusion, this study provides novel insights into long-term
patient-reported outcomes and objective functional impairments
after stroke. The study demonstrated that initial functional
deficits, age and recurrent strokes predict HRQoL, whereas
acute therapies beyond their immediate effect were not clearly
associated with patient-reported outcomes. The subjective health
related quality of life steadily increased for all patients and
recovered to high levels at 12 months despite a high proportion
of persisting disability in up to 29% of the patients. Especially
severely affected patients needed longer periods of time and
improved most between 3 and 12 months. Nevertheless,
after 12 months, the overall health status from the patient’s
perspective did not regain the level of the age-matched
general population. Since objective outcome parameters do
not necessarily match to the same degree as patient-related
outcome measures, these aspects are important for adequate
patient-centered counseling and should be included in future
observational studies.
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MF et al. Validity of EQ-5D-5L in stroke. Qual Life Res. (2015) 24:845–
50. doi: 10.1007/s11136-014-0834-1
8. Hunger M, Sabariego C, Stollenwerk B, Cieza A, Leidl R.
Validity, reliability and responsiveness of the EQ-5D in German
stroke patients undergoing rehabilitation. Qual Life Res. (2012)
21:1205–16. doi: 10.1007/s11136-011-0024-3
9. Pinto EB, Maso I, Vilela RNR, Santos LC, Oliveira-Filho J. Validation of the
EuroQol quality of life questionnaire on stroke victims. Arq Neuropsiquiatr.
(2011) 69:320–3. doi: 10.1590/S0004-282X2011000300010
10. Quinn TJ, Dawson J, Walters MR, Lees KR. Functional outcome
measures in contemporary stroke trials. Int J Stroke. (2009)
4:200–5. doi: 10.1111/j.1747-4949.2009.00271.x
11. EQ-5D-5L-English-User-Guide_version-3.0-Sept-2019-secured.
12. Campbell BCV, Donnan GA, Lees KR, Hacke W, Khatri P, Hill
MD et al. Endovascular stent thrombectomy: the new standard
of care for large vessel ischaemic stroke. Lancet Neurol. (2015)
14:846–54. doi: 10.1016/S1474-4422(15)00140-4
13. Mazighi M, Meseguer E, Labreuche J, Amarenco P. Bridging therapy in
acute ischemic stroke: a systematic review and meta-analysis. Stroke. (2012)
43:1302–8. doi: 10.1161/STROKEAHA.111.635029
14. Shi Z-S, Loh Y, Walker G, Duckwiler GR. Endovascular thrombectomy for
acute ischemic stroke in failed intravenous tissue plasminogen activator versus
non-intravenous tissue plasminogen activator patients: revascularization and
outcomes stratified by the site of arterial occlusions. Stroke. (2010) 41:1185–
92. doi: 10.1161/STROKEAHA.109.568451
15. Ertl M, Meisinger C, Linseisen J, Baumeister S-E, Zickler P, Naumann M.
Long-term outcomes in patients with stroke after in-hospital treatment-
study protocol of the prospective stroke cohort Augsburg (SCHANA Study).
Medicina. (2020) 56:280. doi: 10.3390/medicina56060280
16. Huy C, Schneider S. Instrument für die Erfassung der physischen Aktivität bei
Personen immittleren und höheren Erwachsenenalter: Entwicklung, Prüfung
undAnwendung des “German-PAQ-50+”. ZGerontol Geriatr. (2008) 41:208–
16. doi: 10.1007/s00391-007-0474-y
17. Golicki D, Niewada M, Buczek J, Karlinska A, Kobayashi A, Janssen MF
et al. Validity of the Eq-5d-5l in stroke patients. Value Health. (2014)
17:A570. doi: 10.1016/j.jval.2014.08.1906
18. Li Kwah K, Diong J. National Institutes of Health Stroke Scale (NIHSS). J
Physiother. (2014) 60:61. doi: 10.1016/j.jphys.2013.12.012
19. Banks JL, Marotta CA. Outcomes validity and reliability of
the modified Rankin scale: implications for stroke clinical
trials: a literature review and synthesis. Stroke. (2007) 38:1091–
6. doi: 10.1161/01.STR.0000258355.23810.c6
Frontiers in Neurology | www.frontiersin.org 9 October 2021 | Volume 12 | Article 715313
Kainz et al. Quality of Life After Stroke
20. Berger K, Weltermann B, Kolominsky-Rabas P, Meves S, Heuschmann P,
Böhner J et al. Untersuchung zur Reliabilität von Schlanganfallskalen. Die
deutschen Versionen von NIHSS, ESS und Rankin Scale. Fortschr Neurol
Psychiatr. (1999) 67:81–93. doi: 10.1055/s-2007-993985
21. Muruet W, Rudd A, Wolfe CDA, Douiri A. Long-term survival
after intravenous thrombolysis for ischemic stroke: a propensity
score-matched cohort with up to 10-year follow-up. Stroke. (2018)
49:607–13. doi: 10.1161/STROKEAHA.117.019889
22. McCarthy DJ, Diaz A, Sheinberg DL, Snelling B, Luther EM, Chen SH
et al. Long-term outcomes of mechanical thrombectomy for stroke: a meta-
analysis. Sci World J. (2019) 2019:7403104. doi: 10.1155/2019/7403104
23. Joundi RA, Rebchuk AD, Field TS, Smith EE, Goyal M, Demchuk AM et al.
Health-related quality of life among patients with acute ischemic stroke
and large vessel occlusion in the ESCAPE trial. Stroke. (2021) 52:1636–
42. doi: 10.1161/str.52.suppl_1.P521
24. Deb-Chatterji M, Konnopka A, Flottmann F, Leischner H, Fiehler J,
Gerloff C et al. Patient-reported, health-related, quality of life after
stroke thrombectomy in clinical practice. Neurology. (2020) 95:e1724–
32. doi: 10.1212/WNL.0000000000010356
25. Catto JWF, Downing A, Mason S, Wright P, Absolom K,
Bottomley S et al. Quality of life after bladder cancer: a cross-
sectional survey of patient-reported outcomes. Eur Urol. (2021)
79:621–32. doi: 10.1016/j.eururo.2021.01.032
26. Razdan SN, Patel V, Jewell S, McCarthy CM. Quality of life
among patients after bilateral prophylactic mastectomy: a systematic
review of patient-reported outcomes. Qual Life Res. (2016)
25:1409–21. doi: 10.1007/s11136-015-1181-6
27. Lo Buono V, Corallo F, Bramanti P, Marino S. Coping strategies and
health-related quality of life after stroke. J Health Psychol. (2017) 22:16–
28. doi: 10.1177/1359105315595117
28. Huber MB, Felix J, Vogelmann M, Leidl R. Health-related quality of life of the
general German population in 2015: results from the EQ-5D-5L. Int J Environ
Res Public Health. (2017) 14:426. doi: 10.3390/ijerph14040426
29. Borchert K, Jacob C, Wetzel N, Jänicke M, Eggers E, Sauer A et al.
Application study of the EQ-5D-5L in oncology: linking self-reported
quality of life of patients with advanced or metastatic colorectal cancer
to clinical data from a German tumor registry. Health Econ Rev. (2020)
10:40. doi: 10.1186/s13561-020-00297-6
30. Wit L, Theuns P, Dejaeger E, Devos S, Gantenbein AR, Kerckhofs E, et al.
Long-term impact of stroke on patients’ health-related quality of life. Disabil
Rehabil. (2017) 39:1435–40. doi: 10.1080/09638288.2016.1200676
31. Grenthe Olsson B, Sunnerhagen KS. Functional and cognitive capacity
and health-related quality of life 2 years after day hospital rehabilitation
for stroke: a prospective study. J Stroke Cerebrovasc Dis. (2007) 16:208–
15. doi: 10.1016/j.jstrokecerebrovasdis.2007.06.002
32. Luengo-Fernandez R, Gray AM, Bull L,Welch S, Cuthbertson F, Rothwell PM.
Quality of life after TIA and stroke: ten-year results of the Oxford Vascular
Study. Neurology. (2013) 81:1588–95. doi: 10.1212/WNL.0b013e3182a9f45f
33. Xie J, Wu EQ, Zheng Z-J, Croft JB, Greenlund KJ, Mensah GA
et al. Impact of stroke on health-related quality of life in the
noninstitutionalized population in the United States. Stroke. (2006)
37:2567–72. doi: 10.1161/01.STR.0000240506.34616.10
34. López Espuela F, Portilla Cuenca JC, Leno Díaz C, Párraga Sánchez JM,
Gamez-Leyva G, Casado Naranjo I. Sex differences in long-term quality of
life after stroke: Influence of mood and functional status. Neurologia. (2020)
35:470–8. doi: 10.1016/j.nrleng.2017.10.002
35. Bigourdan A, Munsch F, Coupé P, Guttmann CRG, Sagnier S, Renou
P et al. Early fiber number ratio is a surrogate of corticospinal tract
integrity and predicts motor recovery after stroke. Stroke. (2016) 47:1053–
9. doi: 10.1161/STROKEAHA.115.011576
36. Carod-Artal FJ, Egido JA. Quality of life after stroke: the
importance of a good recovery. Cerebrovasc Dis. (2009) 27(Suppl.
1):204–14. doi: 10.1159/000200461
37. Oemrawsingh A, van Leeuwen N, Venema E, Limburg M, Leeuw FE, Wijffels
MP, et al. Value-based healthcare in ischemic stroke care: case-mix adjustment
models for clinical and patient-reported outcomes. BMC Med Res Methodol.
(2019) 19:229. doi: 10.1186/s12874-019-0864-z
38. Mukundan G, Seidenwurm DJ. Economic and societal aspects
of stroke management. Neuroimaging Clin North Am. (2018)
28:683–9. doi: 10.1016/j.nic.2018.06.009
39. Ghatnekar O, Persson U, Asplund K, Glader E-L. Costs for stroke in Sweden
2009 and developments since (1997). Int J Technol Assess Health Care. (2014)
30:203–9. doi: 10.1017/S0266462314000075
40. Holmes MM, Stanescu S, Bishop FL. The use of measurement systems to
support patient self-management of long-term conditions: an overview of
opportunities and challenges. Patient Relat Outcome Meas. (2019) 10:385–
94. doi: 10.2147/PROM.S178488
41. Bruijn MAAM, Synhaeve NE, van Rijsbergen MWA, Leeuw FE, Mark RE,
Jansen BPW et al. Quality of life after young ischemic stroke of mild severity
is mainly influenced by psychological factors. J Stroke Cerebrovasc Dis. (2015)
24:2183–8. doi: 10.1016/j.jstrokecerebrovasdis.2015.04.040
42. Rachpukdee S, Howteerakul N, Suwannapong N, Tang-Aroonsin S.
Quality of life of stroke survivors: a 3-month follow-up study. J Stroke
Cerebrovasc Dis. (2013) 22:e70–8. doi: 10.1016/j.jstrokecerebrovasdis.2012.
05.005
43. Arwert HJ, Schults M, Meesters JJL, Wolterbeek R, Boiten J, Vliet
Vlieland T. Return to work 2-5 years after stroke: a cross sectional
study in a hospital-based population. J Occup Rehabil. (2017) 27:239–
46. doi: 10.1007/s10926-016-9651-4
44. Bayerische Arbeitsgemeinschaft für Qualitätsicherung in der stationären
Versorgung. Jahresauswertung Gesamt: Schlaganfall (2020). Available online
at: URL: https://www.baq-bayern.de/media/file/1721.2019_851_BA_Gesamt.
pdf (accessed January 2, 2020).
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Publisher’s Note: All claims expressed in this article are solely those of the authors
and do not necessarily represent those of their affiliated organizations, or those of
the publisher, the editors and the reviewers. Any product that may be evaluated in
this article, or claim that may be made by its manufacturer, is not guaranteed or
endorsed by the publisher.
Copyright © 2021 Kainz, Meisinger, Linseisen, Kirchberger, Zickler, Naumann and
Ertl. This is an open-access article distributed under the terms of the Creative
Commons Attribution License (CC BY). The use, distribution or reproduction in
other forums is permitted, provided the original author(s) and the copyright owner(s)
are credited and that the original publication in this journal is cited, in accordance
with accepted academic practice. No use, distribution or reproduction is permitted
which does not comply with these terms.
Frontiers in Neurology | www.frontiersin.org 10 October 2021 | Volume 12 | Article 715313
